How to buy Agenus stock (AGEN)

Agenus is a biotechnology business based in the US. Agenus shares (AGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.96 – a decrease of 9.63% over the previous week. Agenus employs 389 staff and has a trailing 12-month revenue of around $160.4 million.

Our top picks for where to buy Agenus stock

Buy Agenus stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Agenus stock price (NASDAQ: AGEN)

Use our graph to track the performance of AGEN stocks over time.

Agenus shares at a glance

• Key figures

Information last updated 2024-12-11.

Latest market close	$2.96
52-week range	$2.50 - $19.69
50-day moving average more info button	$3.94
200-day moving average more info button	$8.63
Wall St. target price	$8.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-11.02

Is it a good time to buy Agenus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Agenus price performance over time

Historical closes compared with the close of $2.83 from 2024-12-16

1 week (2024-12-11)	-13.46%
1 month (2024-11-19)	10.12%
3 months (2024-09-18)	-53.22%
6 months (2024-06-18)	-78.21%

1 year (2023-12-18)	294.15%
2 years (2022-12-16)	-93.97%
3 years (2021-12-17)	69.8689
5 years (2019-12-18)	72.4203

Agenus financials

Revenue TTM	$160.4 million
Gross profit TTM	$82.6 million
Return on assets TTM	-21.95%
Return on equity TTM	-1278.83%
Profit margin	-141.9%
Book value	$-13.48
Market Capitalization more info button	$77.2 million

TTM: trailing 12 months

Agenus share dividends

We're not expecting Agenus to pay a dividend over the next 12 months.

Have Agenus's shares ever split?

Agenus's shares were split on a 1:20 basis on 11 April 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Agenus shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Agenus shares which in turn could have impacted Agenus's share price.

Agenus share price volatility

Over the last 12 months, Agenus's shares have ranged in value from as little as $2.5 up to $19.688. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agenus's is 1.386. This would suggest that Agenus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Agenus overview

Agenus Inc. , a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks.

Frequently asked questions

null
What percentage of Agenus is owned by insiders or institutions?
Currently 1.267% of Agenus shares are held by insiders and 37.14% by institutions. How many people work for Agenus?
Latest data suggests 389 work at Agenus. When does the fiscal year end for Agenus?
Agenus's fiscal year ends in December. Where is Agenus based?
Agenus's address is: 3 Forbes Road, Lexington, MA, United States, 02421-7305 What is Agenus's ISIN number?
Agenus's international securities identification number is: US00847G7051 What is Agenus's CUSIP number?
Agenus's Committee on Uniform Securities Identification Procedures number is: 037032109